Alex [on behalf of Marie]'s questions to Delcath Systems Inc (DCTH) leadership • Q3 2024
Question
Alex asked for clarification on whether the anticipated Q4 slowdown in treatments due to the holiday season would become a recurring seasonal pattern and inquired about the expected increase in R&D spending for the new trials in 2025.
Answer
CEO Gerard Michel confirmed that he expects some seasonality moving forward, estimating a 1.5 to 2-week reduction in treatment days in Q4 as patients delay procedures for the holidays, but emphasized this is deferred, not lost, revenue. SVP of Finance Sandra Pennell stated that Q4 R&D expenses would be flat with Q3, but projected full-year 2025 R&D to range between $35 million and $40 million to fund the new clinical trials.